Concepts (262)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 14 | 2020 | 655 | 1.030 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 6 | 2023 | 67 | 0.930 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 9 | 2016 | 26 | 0.790 |
Why?
|
| Diet, Western | 6 | 2025 | 19 | 0.780 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 13 | 0.620 |
Why?
|
| Spectrophotometry | 1 | 2019 | 34 | 0.620 |
Why?
|
| Enzymes | 1 | 2019 | 22 | 0.620 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 5 | 2025 | 53 | 0.610 |
Why?
|
| Mitochondria | 5 | 2020 | 342 | 0.590 |
Why?
|
| Liver | 12 | 2025 | 424 | 0.570 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2025 | 100 | 0.570 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2024 | 122 | 0.480 |
Why?
|
| Diabetes, Gestational | 4 | 2020 | 67 | 0.480 |
Why?
|
| Pregnancy | 16 | 2025 | 1154 | 0.480 |
Why?
|
| Adiposity | 5 | 2022 | 88 | 0.420 |
Why?
|
| Liver Cirrhosis | 2 | 2025 | 67 | 0.410 |
Why?
|
| Inflammation | 6 | 2018 | 608 | 0.350 |
Why?
|
| Fatty Liver | 5 | 2012 | 55 | 0.340 |
Why?
|
| Fatty Acids | 3 | 2017 | 202 | 0.320 |
Why?
|
| Pediatric Obesity | 2 | 2022 | 71 | 0.310 |
Why?
|
| Birth Weight | 2 | 2020 | 63 | 0.310 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 35 | 0.290 |
Why?
|
| Muscle, Skeletal | 5 | 2016 | 622 | 0.280 |
Why?
|
| Bile Acids and Salts | 2 | 2025 | 21 | 0.270 |
Why?
|
| Animals | 22 | 2025 | 10093 | 0.270 |
Why?
|
| Diet, High-Fat | 4 | 2022 | 134 | 0.260 |
Why?
|
| Female | 21 | 2025 | 14662 | 0.260 |
Why?
|
| Oxidative Stress | 6 | 2022 | 635 | 0.260 |
Why?
|
| Lipid Metabolism | 5 | 2022 | 122 | 0.260 |
Why?
|
| Insulin Resistance | 3 | 2015 | 172 | 0.250 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 108 | 0.230 |
Why?
|
| Lipoprotein Lipase | 2 | 2018 | 10 | 0.230 |
Why?
|
| Tryptophan | 1 | 2024 | 39 | 0.220 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2024 | 25 | 0.220 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2017 | 42 | 0.220 |
Why?
|
| Maternal Exposure | 2 | 2021 | 17 | 0.210 |
Why?
|
| Fenofibrate | 2 | 2016 | 8 | 0.210 |
Why?
|
| Insulins | 1 | 2022 | 6 | 0.200 |
Why?
|
| Mice | 13 | 2024 | 4478 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2024 | 214 | 0.190 |
Why?
|
| Electron Transport | 2 | 2019 | 30 | 0.180 |
Why?
|
| PQQ Cofactor | 2 | 2022 | 7 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2020 | 847 | 0.180 |
Why?
|
| Infant Formula | 1 | 2020 | 18 | 0.180 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2020 | 21 | 0.180 |
Why?
|
| Endoplasmic Reticulum | 3 | 2010 | 77 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 325 | 0.170 |
Why?
|
| Fatty Acid Desaturases | 1 | 2020 | 15 | 0.170 |
Why?
|
| Male | 14 | 2025 | 13040 | 0.170 |
Why?
|
| Transgenes | 1 | 2020 | 59 | 0.170 |
Why?
|
| Breast Feeding | 1 | 2020 | 87 | 0.170 |
Why?
|
| Placenta | 2 | 2018 | 74 | 0.160 |
Why?
|
| Mothers | 3 | 2018 | 112 | 0.160 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2020 | 55 | 0.160 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 2 | 2012 | 6 | 0.160 |
Why?
|
| Antioxidants | 2 | 2023 | 221 | 0.160 |
Why?
|
| Fetus | 2 | 2025 | 77 | 0.160 |
Why?
|
| Aconitate Hydratase | 1 | 2019 | 4 | 0.160 |
Why?
|
| Macrophages | 3 | 2024 | 280 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 357 | 0.150 |
Why?
|
| Gluconeogenesis | 4 | 2018 | 16 | 0.150 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 626 | 0.140 |
Why?
|
| Hypoxia | 1 | 2018 | 85 | 0.140 |
Why?
|
| Gene Expression | 2 | 2017 | 408 | 0.140 |
Why?
|
| Adipose Tissue | 3 | 2018 | 180 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 1498 | 0.140 |
Why?
|
| Insulin | 4 | 2015 | 315 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2017 | 149 | 0.130 |
Why?
|
| Diet | 2 | 2016 | 226 | 0.130 |
Why?
|
| Humans | 16 | 2022 | 27169 | 0.120 |
Why?
|
| Diet, Fat-Restricted | 1 | 2015 | 5 | 0.120 |
Why?
|
| Diet, Diabetic | 1 | 2015 | 4 | 0.120 |
Why?
|
| Bone Marrow | 1 | 2016 | 76 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2016 | 95 | 0.120 |
Why?
|
| Hepacivirus | 2 | 2012 | 47 | 0.120 |
Why?
|
| Cholesterol | 1 | 2016 | 182 | 0.120 |
Why?
|
| Adenylate Kinase | 2 | 2014 | 8 | 0.120 |
Why?
|
| Response Elements | 2 | 2011 | 21 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2022 | 387 | 0.110 |
Why?
|
| Muscle Proteins | 1 | 2014 | 55 | 0.110 |
Why?
|
| Calcium Signaling | 1 | 2014 | 68 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 73 | 0.110 |
Why?
|
| Adult | 7 | 2022 | 7506 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2010 | 130 | 0.110 |
Why?
|
| Electron Transport Complex II | 1 | 2013 | 5 | 0.110 |
Why?
|
| Sirtuin 3 | 1 | 2013 | 18 | 0.110 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2013 | 12 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 69 | 0.100 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2012 | 5 | 0.100 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2012 | 7 | 0.100 |
Why?
|
| Mitochondria, Liver | 1 | 2012 | 12 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 13 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2012 | 10 | 0.100 |
Why?
|
| Adipose Tissue, Brown | 1 | 2012 | 14 | 0.100 |
Why?
|
| Genome, Viral | 1 | 2012 | 28 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2012 | 32 | 0.100 |
Why?
|
| Primates | 2 | 2023 | 22 | 0.100 |
Why?
|
| Macaca | 2 | 2025 | 19 | 0.100 |
Why?
|
| Triglycerides | 4 | 2018 | 121 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2012 | 58 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2012 | 70 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 164 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 1406 | 0.090 |
Why?
|
| Child | 3 | 2022 | 2159 | 0.090 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2010 | 5 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 93 | 0.090 |
Why?
|
| Mesoderm | 1 | 2010 | 12 | 0.090 |
Why?
|
| Hepatocytes | 1 | 2011 | 75 | 0.090 |
Why?
|
| Adipocytes, White | 1 | 2010 | 10 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2010 | 26 | 0.090 |
Why?
|
| Infant | 3 | 2018 | 965 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2009 | 22 | 0.080 |
Why?
|
| Receptors, Adiponectin | 1 | 2009 | 5 | 0.080 |
Why?
|
| Phenylbutyrates | 1 | 2009 | 3 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2010 | 241 | 0.080 |
Why?
|
| Interleukin-10 | 2 | 2024 | 68 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 133 | 0.080 |
Why?
|
| Adolescent | 3 | 2022 | 2993 | 0.070 |
Why?
|
| Biomarkers | 2 | 2022 | 738 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2022 | 221 | 0.070 |
Why?
|
| Glucose Tolerance Test | 3 | 2014 | 59 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2022 | 1221 | 0.070 |
Why?
|
| PPAR alpha | 2 | 2022 | 32 | 0.070 |
Why?
|
| Enzyme Activation | 3 | 2012 | 265 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2017 | 355 | 0.060 |
Why?
|
| Blood Glucose | 3 | 2015 | 307 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2012 | 1271 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 489 | 0.060 |
Why?
|
| Young Adult | 3 | 2017 | 2633 | 0.060 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2016 | 16 | 0.060 |
Why?
|
| Carnitine O-Palmitoyltransferase | 2 | 2017 | 10 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 213 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2005 | 78 | 0.060 |
Why?
|
| Rats | 3 | 2012 | 1554 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 80 | 0.050 |
Why?
|
| PPAR gamma | 2 | 2016 | 29 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2012 | 795 | 0.050 |
Why?
|
| Endotoxins | 1 | 2022 | 27 | 0.050 |
Why?
|
| Fibrosis | 1 | 2023 | 121 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 440 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2017 | 398 | 0.050 |
Why?
|
| Uterus | 1 | 2021 | 31 | 0.050 |
Why?
|
| Lipids | 2 | 2016 | 199 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2012 | 25 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 156 | 0.050 |
Why?
|
| Longevity | 1 | 2022 | 129 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2016 | 978 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2014 | 568 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 29 | 0.040 |
Why?
|
| Phenotype | 1 | 2023 | 668 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 267 | 0.040 |
Why?
|
| Cytokines | 2 | 2016 | 441 | 0.040 |
Why?
|
| Thapsigargin | 2 | 2010 | 8 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2020 | 58 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 989 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2018 | 3 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 15 | 0.040 |
Why?
|
| Fatty Acids, Volatile | 1 | 2018 | 15 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 458 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2012 | 1379 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2009 | 33 | 0.040 |
Why?
|
| Bacteria | 1 | 2020 | 264 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 325 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 598 | 0.040 |
Why?
|
| Feces | 1 | 2018 | 107 | 0.040 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2017 | 4 | 0.040 |
Why?
|
| Glucose | 2 | 2012 | 199 | 0.040 |
Why?
|
| Muscle Development | 1 | 2017 | 9 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2009 | 506 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 186 | 0.030 |
Why?
|
| Umbilical Cord | 1 | 2017 | 35 | 0.030 |
Why?
|
| Hypoglycemic Agents | 2 | 2008 | 106 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 82 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 39 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 281 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 2038 | 0.030 |
Why?
|
| Ceramides | 1 | 2016 | 24 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 68 | 0.030 |
Why?
|
| Prediabetic State | 1 | 2016 | 10 | 0.030 |
Why?
|
| Foam Cells | 1 | 2016 | 8 | 0.030 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2016 | 5 | 0.030 |
Why?
|
| RAW 264.7 Cells | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2016 | 24 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 31 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 707 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 36 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 64 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2015 | 22 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2015 | 5 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 189 | 0.030 |
Why?
|
| Fasting | 1 | 2015 | 80 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 110 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2017 | 469 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 397 | 0.030 |
Why?
|
| Glutathione | 1 | 2013 | 70 | 0.030 |
Why?
|
| Proteomics | 1 | 2014 | 177 | 0.030 |
Why?
|
| Liver X Receptors | 1 | 2012 | 21 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 58 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2012 | 5 | 0.030 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 58 | 0.030 |
Why?
|
| Secretory Vesicles | 1 | 2012 | 12 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2012 | 28 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2012 | 29 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2012 | 12 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 21 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 21 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 34 | 0.030 |
Why?
|
| Luciferases | 1 | 2012 | 49 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2012 | 28 | 0.020 |
Why?
|
| Inflammasomes | 1 | 2012 | 20 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 87 | 0.020 |
Why?
|
| Virus Replication | 1 | 2012 | 63 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 116 | 0.020 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2011 | 19 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 2011 | 20 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2011 | 29 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 331 | 0.020 |
Why?
|
| Adipocytes, Brown | 1 | 2010 | 2 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2012 | 246 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 8 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2010 | 45 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2010 | 123 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 190 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2010 | 90 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2009 | 21 | 0.020 |
Why?
|
| Tunicamycin | 1 | 2009 | 3 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 20 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 143 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2008 | 12 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 452 | 0.020 |
Why?
|
| RNA | 1 | 2009 | 105 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 637 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2008 | 100 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 725 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 448 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 446 | 0.020 |
Why?
|
| Acute-Phase Reaction | 1 | 2007 | 4 | 0.020 |
Why?
|
| Choline Deficiency | 1 | 2007 | 5 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2007 | 7 | 0.020 |
Why?
|
| Lipase | 1 | 2007 | 10 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2007 | 6 | 0.020 |
Why?
|
| Palmitates | 1 | 2007 | 9 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2007 | 29 | 0.020 |
Why?
|
| Methionine | 1 | 2007 | 37 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2007 | 17 | 0.020 |
Why?
|
| Metformin | 1 | 2007 | 34 | 0.020 |
Why?
|
| Body Composition | 1 | 2008 | 262 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 5234 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 648 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 188 | 0.020 |
Why?
|
| Body Weight | 1 | 2007 | 247 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 243 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2007 | 186 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 6913 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 683 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 590 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1571 | 0.010 |
Why?
|